Name: Yi-Chao Zheng

Qualification: PhD

Country: China


Zhengzhou University

Email: Send an Email


Zhengzhou University,
100 Kexue Avenue,

Research Interests:

Epigenetics, Medicinal Chemistry in Epigenetics, Clinical Application of Small Molecules, Personalize Medicine, Multiple Drug Resistance, Tumor Metastasis.



  • China Pharmaceutical University, Nanjing, China    B.A.    2008    Pharmaceutics
  • Katholieke Universiteit Leuven, Leuven, Belgium    M.S.    2009    Pharmaceutical Analysis
  • Zhengzhoul University, Zhengzhou, China    Ph.D.    2014    Medicinal Chemistry


  • 2016,12-Present: Associate Professor, School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou, Henan, China
  • 2014,7-2016, 12: Lecturer, School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou, Henan, China
  • 2010.9-2014.7: Ph.D., School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou, Henan, China
  • 2009,9-2010,9: Research assistant, Dpartment of Radiology, University Hospitals Leuven, Leuven, Belgium


  1. Ying-Chao Duan, Yuan-Yuan Guan, Xiao-Yu Zhai, Li-Na Ding, Wen-Ping Qin, Dan-Dan Shen, Xue-Qi Liu, Xu-Dong Sun, Yi-Chao Zheng*, Hong-Min Liu*. Discovery of resveratrol derivatives as novel LSD1 inhibitors: Design, synthesis and their biological evaluation. European Journal of Medicinal Chemistry. 2017, 126, 246-258.
  2. Yi-Chao Zheng, Dan-Dan Shen, Meng Ren, Xue-Qi Liu, Zhi-Ru Wang, Ying Liu, Qian-Na Zhang, Li-Juan Zhao, Li-Jie Zhao, Jin-Lian Ma, Bin-Yu, Hong-Min Liu. Baicalin, a natural LSD1 inhibitor. Bioorganic Chemistry. 2016, 69, 129-131. 
  3. Shuai Wang, Li-Jie Zhao, Yi-Chao Zheng, Dan-Dan Shen, Er-Fei Miao, Xue-Peng Qiao, Li-Juan Zhao, Ying Liu, Ruilei Huang, Bin Yu, Hong-Min Liu. Design, synthesis and biological evaluation of [1,2,4]triazolo[1,5-a]pyrimidines as potent lysine specific demethylase 1 (LSD1/KDM1A) inhibitors. European Journal of Medicinal Chemistry. 2016, 125, 940-951. 
  4. Yi-Chao Zheng, Jin-Lian Ma, Ying Liu, Hong-Min Liu*.Writers and Erasers of Histone Lysine methylation with Clinical Applied Modulators Promising Target for Cancer Therapy. Current Pharmaceutical Design. 2016, 22, 1-5. 
  5. Yi-Chao Zheng, Bin Yu, Zhe-Sheng Chen, Ying Liu and Hong-Min Liu*. TCPs: privileged scaffolds for identifying potent LSD1 inhibitors for cancer therapy. Epigenomics. 2016, 8(5), 651-666. 
  6. Yi-Chao Zheng, Bin Yu, Guo-Zhong Jiang, Xue-Jian Feng, Peng-Xing He, Xiao-Yang Chu, Wen Zhao, Hong-Min Liu*. Irreversible LSD1 inhibitors: Application of tranylcypromine and its derivates in cancer. Current Topics in Medicinal Chemistry. 2016, 16(19): 2179-2188. 
  7. Yi-Chao Zheng, Long-Zhen Wang, Li-Jie Zhao, Li-Juan Zhao, Qian-Na Zhan, Jin-Lian Ma, Bin Zhang, Meng-Meng Wang, Zhi-Ru Wang, Jin-Feng Li, Ying Liu, Zhe-Sheng Chen, Dan-Dan Shen, Xue-Qi Liu, Meng Ren, Wen-Lei Lv, Wen Zhao, Ying-Chao Duan, Hong-Min Liu1*. 1,2,3-triazole–dithiocarbamate hybrids, a group of novel cell active SIRT1 inhibitors.  Cellular Physiology and Biochemistry. 2016, 38(1):185-193.
  8. Yi-Chao Zheng, Jinlian Ma, Zhiru Wang, Jinfeng Li, Bailing Jiang, Wenjuan Zhou, Xiaojing Shi, Xixin Wang, Wen Zhao and Hong-Min Liu*. A Systematic Review of Histone Lysine-Specific Demethylase 1 and Its Inhibitors. Medicinal Research Reviews, 2015, 35, 1032-1071.
  9. Bin Yu, Yi-Chao Zheng, Xiao-Jing Shi, Ping-Ping Qi and Hong-Min Liu*. Natural product-derived spirooxindole fragments serve as privileged substructures for discovery of new anticancer agents. Anti-Cancer Agents in Medicinal Chemistry, 2015, DOI: 10.2174/1871520615666151102093825
  10. Li-Ying Ma, Yi-Chao Zheng (Joint first author), Sai-Qi Wang, Bo Wang, Zhi-Ru Wang, Lu-Ping Pang, Miao-Zhang, Jun-Wei Wang, Li-Na Ding, Juan Li, Cong Wang, Biao Hu, Ying Liu, Xiao-Dan Zhang, Jia-Jia Wang, Zhi-Jian Wang, Wen Zhao* and Hong-Ming Liu*. Design, synthesis and structure-activity relationship of novel LSD1 inhibitors based on pyrimidine-thiourea-hybrids as potent, orally active antitumor agents. Journal of Medicinal Chemistry, 2015, 58(4):1705-1716.

Copy right